KWA
NVO

KCS Wealth Advisory’s Novo Nordisk NVO Stock Holding History

KCS Wealth Advisory’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.73M Sell
40,974
-4,862
-11% -$428K 1.59% 12
2023
Q2 		$3.71M Sell
45,836
-720
-2% -$58.8K 1.29% 15
2023
Q1 		$3.7M Sell
46,556
-296
-0.6% -$21K 1.4% 11
2022
Q4 		$3.17M Sell
46,852
-6,870
-13% -$403K 1.32% 13
2022
Q3 		$2.68M Sell
53,722
-6,486
-11% -$347K 1.23% 16
2022
Q2 		$3.35M Buy
60,208
+968
+2% +$53.7K 1.49% 11
2022
Q1 		$3.29M Buy
59,240
+3,034
+5% +$156K 1.52% 13
2021
Q4 		$3.15M Buy
56,206
+1,250
+2% +$67.7K 1.26% 17
2021
Q3 		$2.64M Buy
54,956
+2,884
+6% +$139K 1.25% 19
2021
Q2 		$2.18M Buy
52,072
+9,594
+23% +$372K 1.03% 25
2021
Q1 		$1.43M Buy
42,478
+25,932
+157% +$924K 0.74% 43
2020
Q4 		$578K Buy
16,546
+10,586
+178% +$366K 0.38% 88
2020
Q3 		$207K Sell
5,960
-1,808
-23% -$60.3K 0.17% 135
2020
Q2 		$254K Hold
7,768
– – 0.21% 125
2020
Q1 		$234K Sell
7,768
-1,398
-15% -$41.6K 0.24% 117
2019
Q4 		$265K Sell
9,166
-766
-8% -$21.2K 0.2% 131
2019
Q3 		$257K Sell
9,932
-120
-1% -$3.03K 0.18% 133
2019
Q2 		$257K Hold
10,052
– – 0.2% 133
2019
Q1 		$263K Sell
10,052
-368
-4% -$9.04K 0.23% 125
2018
Q4 		$240K Sell
10,420
-1,482
-12% -$32.9K 0.25% 130
2018
Q3 		$281K Sell
11,902
-6,024
-34% -$147K 0.26% 126
2018
Q2 		$413K Sell
17,926
-4,626
-21% -$110K 0.38% 103
2018
Q1 		$555K Sell
22,552
-2,654
-11% -$69.7K 0.5% 84
2017
Q4 		$676K Buy
+25,206
New +$641K 0.65% 53

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCS Wealth Advisory's NVO Position: Q3 2023 in Review

KCS Wealth Advisory reduced its Novo Nordisk (NVO) stake by 11% in Q3 2023, selling an estimated $428K and leaving 40,974 shares worth $3.73M. The position accounts for 1.59% of the portfolio, ranked #12.

KCS Wealth Advisory first reported a position in NVO in Q4 2017 and has held it in 24 quarters since. 1,307 funds tracked by Wall St. Rank hold NVO as of Q3 2023.

  • KCS Wealth Advisory held 40,974 shares of Novo Nordisk worth $3.73M as of Q3 2023.
  • KCS Wealth Advisory sold 4,862 Novo Nordisk shares in Q3 2023, an estimated $428K.
  • Novo Nordisk made up 1.59% of KCS Wealth Advisory's portfolio in Q3 2023, its #12 holding.
  • KCS Wealth Advisory first reported a position in Novo Nordisk in Q4 2017 and has held it in 24 quarters since.
  • 1,307 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2023.

Based on KCS Wealth Advisory's 13F filing for Q3 2023, filed 3 Nov 2023.